Turn on more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Sign In
Skip to main content Open accessibility information page
Alert
On January 16, 2024, Governor Phil Murphy signed the New Jersey Data Privacy Law, P.L. 2023, c. 266. The law went into effect on January 15, 2025. Please click on this Frequently Asked Questions link to learn more about the new law and your rights under it.
Alert
On January 8, 2024, Governor Murphy signed into law P.L. 2023, c. 237, which, among other things: amended the Contractors’ Business Registration Act (“CBRA,” formerly the “Contractors’ Registration Act”), N.J.S.A. 56:8-136 et seq., and created the “Home Improvement and Home Elevation Contractor Licensing Act,” N.J.S.A. 45:5AAA-1 et seq. For more information on the registration requirements for contractors and businesses under these laws, click here.
Alert
On July 10, 2024, Governor Murphy signed into law the Real Estate Consumer Protection Enhancement Act, P.L. 2024, c.32, which, among other things, requires sellers of residential property located in New Jersey to use the "Seller's Property Condition Disclosure Statement" ("Disclosure Statement," questions 1 through 108).

Additionally, on July 3, 2023, Governor Murphy signed into law P.L. 2023, c.93, which, among other things, requires sellers of all real property located in New Jersey to make certain additional disclosures concerning flood risks on the "Disclosure Statement." On July 15, 2024, the Division published a "Flood Risk Addendum" to the Disclosure Statement (questions 109 through 117), which includes the additional disclosures concerning flood risks.

As a result of these two laws, effective August 1, 2024:
  • Sellers of residential property must complete the Disclosure Statement (questions 1 through 108). A copy of the Disclosure Statement is available here; and
  • All sellers of real property, both residential and non-residential, must complete the Flood Risk Addendum to the Disclosure Statement (questions 109 through 117). A copy of the Flood Risk Addendum is available here.

The Division has created an instruction sheet with additional information regarding the use of these forms. The forms linked above supersede any forms previously posted by the Division, including, but not limited to, the "Amended Disclosure Statement" posted on December 21, 2023.

Press Release


For Immediate Release:
April 13, 2015

Office of The Attorney General
John J. Hoffman, Acting Attorney General

Division of Consumer Affairs
Steve C. Lee, Acting Director

Division of Law
Jeffrey S. Jacobson Director
  For Further Information and Media Inquiries:
Jeff Lamm
Neal Buccino
(973) 504-6327

New Jersey Becomes 1st State with App for its Prescription Monitoring Program

NEWARK – Continuing its national leadership in addressing the misuse of prescription drugs, New Jersey this week launched the first-in-the-nation online app that allows authorized users of the state’s Prescription Monitoring Program access to the database via Apple smartphones and handheld devices. The move is another important step in the Christie Administration’s commitment to prevent drug abuse and save lives in the Garden State.

The NJPMP, maintained by the Division of Consumer Affairs, collects detailed information on prescriptions filled in New Jersey for controlled dangerous substances (CDS) – the category of drugs that includes potentially addictive opiate painkillers – and Human Growth Hormone. The NJPMP provides a searchable database to state-licensed prescribers and pharmacists and aids in identifying patients who have engaged in “doctor shopping” – deceptively visiting multiple physicians to obtain more prescription drugs than any one doctor would prescribe – or in trying to illegally obtain prescription drugs through use of multiple pharmacies.

The app is located at https://appsto.re/us/oUv23.i and is free of charge to users. Android and Windows Mobile versions of the app will be available this summer.

“We’re working hard to expand the use of the Prescription Monitoring Program and this new app is the latest in an ongoing series of upgrades to the NJPMP since we launched it in late 2011,” Acting Attorney General John J. Hoffman said. “The more user-friendly we make the NJPMP, the more prescribers and pharmacists will use it. Their participation is of critical importance as we collectively work to address prescription drug abuse.”

As of April 9, 2015, 88.4% of the state’s 29,400 licensed doctors had registered to use the NJPMP database. About 169,000 user requests were submitted to the NJPMP during the preceding 30-day period.

“We’re fostering increased use of the NJPMP. The abuse of prescription drugs is a national issue that we in New Jersey are addressing on multiple fronts,” said Steve Lee, Acting Director of the New Jersey Division of Consumer Affairs. “The ongoing increase in NJPMP registration is welcomed but we strive for even greater participation among prescribers and pharmacists.”

To encourage participation, the Division of Consumer Affairs revised the NJPMP enrollment process after the program launched, granting automatic enrollment to all New Jersey doctors who successfully applied for the renewal of their State-granted authority to prescribe CDS. The Division also launched an outreach campaign, sending staff to hospitals to meet with doctors and explain the NJPMP program to them.

In 2014, the Division expanded the NJPMP to include direct data-sharing with the PMPs maintained by Connecticut and Delaware, and began efforts to build a similar data-sharing partnership with New York State.

###

Last Modified: 4/23/2015 7:40 AM